Duke University

WASHINGTON — In patients with atrial fibrillation requiring stroke prevention, the novel factor XIa inhibitor asundexian was associated with lower bleeding rates compared with apixaban, according to the results of the PACIFIC-AF trial.

The word “candidate” is often used when determining whether a patient with HF will benefit from a particular therapy, but an editorial in the Journal of Cardiac Failure states the term may be too judgmental.

Health care workers experienced high rates of potential moral injury during the COVID-19 pandemic that were comparable to rates among U.S. military veterans who served after Sept. 11, 2001, according to a recent study.

CHICAGO — Should an acute rupture or avulsion of the patellar tendon occur in primary total knee arthroplasty, surgeons should know a variety of techniques to manage this challenging problem, a presenter said.

WASHINGTON — Contrary to guideline recommendations, most patients with infections related to implantable cardiac devices do not get their devices explanted, despite extraction leading to better outcomes, researchers reported.

WASHINGTON — In well-treated patients with chronic HF with reduced ejection fraction, omecamtiv mecarbil did not improve measures of exercise capacity over 20 weeks compared with placebo, researchers reported.

In patients with ACS, the PCSK9 inhibitor alirocumab did not impact the development of atrial fibrillation compared with placebo, according to new data from the ODYSSEY Outcomes trial.

Among adults aged at least 65 years, treatment with a subcutaneous or single-chamber transvenous implantable cardioverter defibrillator was associated with similar outcomes, including all-cause and CV rehospitalization and death.

The Cardiac Safety Research Consortium announced that a pediatric cardiac screening data warehouse has been created and prospective data collection is underway.

An infant believed to be the first to receive a combination heart transplant and allogeneic processed thymus tissue implant is gaining immune function 6 months after the procedures, potentially reducing the need for antirejection drugs.